...
首页> 外文期刊>Intelligence: A Multidisciplinary Journal >Estimation of lipemia interference with automated HIL-test on d-dimer ACL TOP 50 series analysis - reveals a higher cut-off than manufacturer's recommendations
【24h】

Estimation of lipemia interference with automated HIL-test on d-dimer ACL TOP 50 series analysis - reveals a higher cut-off than manufacturer's recommendations

机译:对D-DIMER ACL Top 50系列分析的自动HIL检验的脂质血症干扰的估计 - 揭示了比制造商的建议更高的截止

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Fibrin-d-dimer (d-dimer) is essential for the diagnosis and treatment of thrombosis patients. The new ACL TOP 50- series used for d-dimer determination, integrates a preanalytical interference check for hemolysis, icterus and lipemia (HIL-test). Using earlier versions of ACL TOP, HIL was evaluated by visual inspection by the biomedical laboratory scientist. With the new integrated HIL-test, lipemia is determined by measuring turbidity in the sample at 671 nm, reflecting the lipid content in the sample. Using the new ACL TOP 50- series, we observed more samples being rejected for d-dimer analysis due to lipemia-interference evaluated by the integrated HIL-test suggesting a discrepancy between the former triglyceride-based cut-off and the new turbidity-based cut-off. Therefore, to re-evaluate the lipemia interference cut-off with the turbidimetric measurement, we did a spike-in experiment, using intralipid as lipemia simulation. Three x six different patient pools were prepared from sodium-citrate plasma. We observed no interference in the d-dimer assay by intralipid concentrations resulting in milli absorbances (mAbs) below 3000 mAbs. Thus, the cut-off for lipemia interference using the integrated HIL-test on ACL TOP 550 should be 3000 mAbs. This cut-off will reduce the number of samples rejected due to false positive interference and at the same time reduce 'hands on' time for the biomedical laboratory scientists and minimize the risk of subjective evaluation by a visual inspection.
机译:纤维蛋白-D二聚体(D-二聚体)对于血栓形成患者的诊断和治疗至关重要。用于D-DIMER测定的新型ACL前50系列,整合了溶血,渗透,脂质血症(HIL-TEST)的预译干扰检查。利用早期版本的ACL顶部,通过生物医学实验室科学家的目视检查评估HIL。利用新的集成HIL检验,通过在671nm处测量样品中的浊度来确定脂质血症,反映样品中的脂质含量。使用新的ACL前50系列,我们观察到更多的样品因脂质血症干扰而被拒绝用于D-DIMOR分析,这是通过集成的HIL-TEST评估的,表明前甘油三酯的截止和基于新的浊度之间的差异隔断。因此,重新评估利用浊度测量的脂质血症干扰切断,我们使用introalipid作为脂质血症模拟进行了尖峰实验。由柠檬酸钠等离子体制备三x六种不同的患者池。我们观察到通过鳞癌浓度观察到D-二聚体测定的干扰,导致毫在3000mAb低于3000mAb的毫米吸收剂(mAb)。因此,使用ACL顶部550上的集成HIL检验的脂质血症干扰的截止应为3000mAb。这种截止会减少由于假阳性干扰而被拒绝的样本数量,同时减少生物医学实验室科学家的手机时间,并通过目视检查最大限度地减少主观评价的风险。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号